Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease

ABSTRACT:

Background:

Data on the performance of newer biologics in patients with fistulizing Crohn’s disease (CD) are limited.

Objective:

Our study’s objective was to evaluate the response to ustekinumab (UST) and vedolizumab (VDZ) in patients with fistulizing CD.

Design:

Retrospective cohort.

Methods:

We used natural language processing of electronic medical record data to identify a retrospective cohort of individuals with fistulizing CD at a single academic tertiary-care referral center and then performed a chart review. Individuals were eligible for inclusion if a fistula was present at the time of UST or VDZ initiation. Outcomes included medication discontinuation, surgical intervention, development of a new fistula, and fistula closure. Groups were compared

SUBMITTER:  

PROVIDER: S-EPMC9989393 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature